5.94

13.03% -0.89

After Hours: 5.39 -0.55 -9.26%

Minerva Neurosciences Inc (NERV)

Overview News Price History Financials Discussions Forecast Stock Split

Minerva Neurosciences Inc stock is traded at $5.94, with a volume of 594.40K. It is down -13.03% in the last 24 hours and up +40.76% over the past month. Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Previous Close:

$6.83

Open:

$6.7

24h Volume:

594.40K

Relative Volume:

6.83

Market Cap:

$257.05M

Revenue:

Net Income/Loss:

$-33.65M

P/E Ratio:

-1.3348

EPS:

-4.45

Net Cash Flow:

$-20.83M

1W Performance:

-4.65%

1M Performance:

+40.76%

6M Performance:

+152.77%

1Y Performance:

+257.83%

1-Day Range:

$5.0201

$6.70

1-Week Range:

$5.0201

$7.19

52-Week Range:

$1.15

$12.46

Minerva Neurosciences Inc Stock (NERV) Company Profile

Name

Minerva Neurosciences Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

617-600-7373

Address

1500 DISTRICT AVENUE, BURLINGTON, MA

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

NERV's Discussions on Twitter

Compare NERV vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NERV Minerva Neurosciences Inc	5.94	295.56M	0	-33.65M	-20.83M	-4.45
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Initiated	BTIG Research	Buy
Oct-02-19	Reiterated	Chardan Capital Markets	Buy
Sep-25-19	Initiated	Chardan Capital Markets	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-31-19	Initiated	H.C. Wainwright	Buy
Sep-01-17	Initiated	Citigroup	Buy
Mar-06-17	Resumed	Jefferies	Buy
May-12-16	Resumed	Jefferies	Buy

View All

Minerva Neurosciences Inc Stock (NERV) Latest News

Mar 04, 2026

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference - The Manila Times

Mar 04, 2026

Mar 02, 2026

Fed Meeting: Can Minerva Neurosciences Inc continue delivering strong returnsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn

Mar 02, 2026

Feb 28, 2026

Minerva Neurosciences (NASDAQ:NERV) Upgraded to Hold at Wall Street Zen - MarketBeat

Feb 28, 2026

Feb 27, 2026

Is Minerva Neurosciences Inc. in a consolidation phaseMarket Weekly Review & Risk Controlled Swing Alerts - mfd.ru

Feb 27, 2026

Feb 25, 2026

Minerva Neurosciences (NASDAQ:NERV) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat

Feb 25, 2026

Feb 24, 2026

Weekly Earnings: Can Minerva Neurosciences Inc be recession proofTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn

Feb 24, 2026

Feb 22, 2026

Is Minerva Neurosciences Inc. stock showing strong momentumGold Moves & Fast Moving Trade Plans - mfd.ru

Feb 22, 2026

Feb 21, 2026

Balyasny Asset Management L.P. Acquires Significant Stake in Min - GuruFocus

Feb 21, 2026

Feb 20, 2026

Balyasny Asset Management L.P. Acquires Significant Stake in Minerva Neurosciences Inc. - GuruFocus

Feb 20, 2026

Minerva Neurosciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView

Feb 20, 2026

Coastlands (NASDAQ: NERV) reports 9.99% stake via convertible preferred/warrants - Stock Titan

Feb 20, 2026

Feb 19, 2026

Is Minerva Neurosciences Inc. in a long term uptrendTake Profit & Safe Entry Zone Tips - mfd.ru

Feb 19, 2026

Feb 18, 2026

Aug Swings: What drives MODVs stock priceJuly 2025 Earnings & Accurate Intraday Trading Signals - baoquankhu1.vn

Feb 18, 2026

Feb 17, 2026

Balyasny discloses 4.33M-share Minerva Neurosciences (NERV) position - Stock Titan

Feb 17, 2026

Is Minerva Neurosciences Inc. stock attractive for growth ETFs2025 Growth vs Value & Accurate Buy Signal Notifications - mfd.ru

Feb 17, 2026

Logos Global discloses 9.9% Minerva Neurosciences (NERV) ownership stake - Stock Titan

Feb 17, 2026

Feb 16, 2026

Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap touched US$271m last week, benefiting both retail investors who own 55% as well as institutions - simplywall.st

Feb 16, 2026

Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most - Yahoo Finance

Feb 16, 2026

Minerva Neurosciences, Inc (NASDAQ:NERV) Short Interest Update - MarketBeat

Feb 16, 2026

Feb 14, 2026

Will Minerva Neurosciences Inc. (4MNA) stock see valuation expansionWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru

Feb 14, 2026

Feb 13, 2026